Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company headquartered in Newton, Massachusetts, dedicated to the discovery, development, and commercialization of novel cancer therapies. The company's core business revolves around its proprietary Selective Inhibitor of Nuclear Export (SINE) technology, which targets nuclear export dysregulation, a fundamental mechanism in cancer. Karyopharm's mission is to foster scientific creativity and pioneering technologies to accelerate the development of first-in-class small molecule modulators of nuclear transport into effective therapeutics for life-threatening conditions, ultimately aiming to improve patient lives and defeat cancer.

The company's lead product is XPOVIO® (selinexor), an oral, first-in-class exportin 1 (XPO1) inhibitor. XPOVIO is approved in the U.S. for the treatment of multiple myeloma and diffuse large B-cell lymphoma, and also holds regulatory approvals in other territories, including Europe and the United Kingdom where it is marketed as NEXPOVIO®. Karyopharm maintains a focused pipeline of investigational medicines, including Eltanexor and KPT-9274, targeting various hematologic malignancies and solid tumors such as endometrial cancer and myelofibrosis.

Richard Paulson serves as the President and Chief Executive Officer, having been appointed in May 2021. Recent developments include mixed results from the Phase 3 SENTRY trial evaluating selinexor in combination with ruxolitinib for myelofibrosis, which met one co-primary endpoint but missed another related to symptom improvement. The company also reported a larger-than-expected loss in its first-quarter 2026 earnings, with XPOVIO revenues experiencing stagnation due to toxicity concerns and increased market competition. Karyopharm continues to advance its pipeline, with topline data for the Phase 3 XPORT-EC-042 trial in endometrial cancer anticipated in mid-2026.